Glecaprevir + Pibrentasvir Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Glecaprevir- 100 mg + Pibrentasvir - 40 mg
Reference Brands: Mavyret (US); Maviret (EU)
Category: Anti Viral
Mavyret/Maviret is a once-daily 3-tablet regimen combining Glecaprevir and Pibrentasvir for pan-genotypic HCV treatment. It offers short 8-week therapy, high cure rates, and is safe for patients with kidney or liver issues. Glecaprevir + Pibrentasvir is available in Tablet and strengths such as Glecaprevir- 100 mg + Pibrentasvir - 40 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Glecaprevir + Pibrentasvir is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Glecaprevir + Pibrentasvir can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Mavyret (US) / Maviret (EU) is a fixed-dose combination of Glecaprevir 100 mg and Pibrentasvir 40 mg per tablet, approved by the FDA and EMA for the treatment of chronic hepatitis C virus (HCV) infection across genotypes 1–6. This pan-genotypic regimen is taken as three tablets once daily with food. It offers one of the shortest HCV treatments—just 8 weeks for most patients. Mavyret is highly effective (SVR >95%) and suitable for use in patients with renal impairment and compensated cirrhosis. Its ribavirin-free formulation improves tolerability, making it a convenient, high-efficacy option for diverse patient populations.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Glecaprevir and Pibrentasvir are used together for the treatment of chronic hepatitis C virus (HCV) infection across all major genotypes (1–6). This combination is highly effective and is used in both treatment-naïve and treatment-experienced patients, with or without cirrhosis.
This fixed-dose combination contains glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor. Together, they block viral replication at two different stages of the HCV life cycle, leading to sustained virologic response.
The globally recognized trade name for this combination is Mavyret (also known as Maviret in some regions).
Mavyret/Maviret is manufactured by AbbVie.
The generic name of the product is glecaprevir and pibrentasvir.
The common brand name is Mavyret (or Maviret depending on the market).
Glecaprevir + Pibrentasvir (Mavyret/Maviret) is manufactured by AbbVie in its approved global pharmaceutical production facilities located in the United States and Europe. Generic versions, where permitted, are produced by licensed manufacturers in select countries.
Related Products
Maraviroc
Strength:
150 mg, 300 mg, 20 mg
Form: Tablets / Oral solution
Reference Brands: Selzentry (USA), Celsentri (EU)
View Details
Raltegravir
Strength:
100mg, 400 mg, 600mg
Form: Tablets
Reference Brands: Isentress (USA/EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
